# Indivior Pharmaceuticals, Inc. (INDV)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $4.93B  
**Price:** $38.50 (+1.08%)

> Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treating substance use disorders and related mental health conditions. The company concentrates on evidence-based therapies for opioid use disorder, including long-acting injectable and sublingual formulations designed to support adherence and sustained recovery. Its portfolio also extends to treatments addressing opioid overdose, alcohol dependence, and other addiction-related indications, positioning it as a key player in addiction medicine. Indivior Pharmaceuticals, Inc. integrates neuroscience, clinical research, and real-world data to develop and optimize therapies for chronic, relapsing conditions associated with substance use. The company works with healthcare providers, treatment centers, and public health systems, supplying products and clinical support across multiple regions. Founded in 1994 and headquartered in the United States, Indivior Pharmaceuticals, Inc. plays a significant role in the global effort to address opioid use disorder and other substance-related health burdens through specialized pharmacological treatments.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.24B | $994M | $262M | $210M | $1.64 |
| 2024 | $1.19B | $957M | $38M | $7M | $0.05 |
| 2023 | $1.09B | $919M | -$152M | -$126M | $-0.92 |
| 2022 | $901M | $749M | -$81M | -$44M | $-0.32 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.20B | $1.30B | -$98M | $195M | $290M |
| 2024 | $1.32B | $1.65B | -$337M | $319M | $315M |
| 2023 | $1.76B | $1.94B | -$184M | $316M | $237M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$27M | $66M | -$93M |
| 2024 | $36M | $29M | $7M |
| 2023 | -$300M | $8M | -$308M |
| 2022 | -$4M | $5M | -$9M |

Source: [CompaniesByCap](https://companiesbycap.com/company/INDV)